{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:06:24Z","timestamp":1783472784507,"version":"3.55.0"},"reference-count":43,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,7,27]],"date-time":"2005-07-27T00:00:00Z","timestamp":1122422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> Quality of life has been assessed in a large, multicentre randomized, open label study.<\/jats:p><jats:p><jats:bold>Aim:\u2002<\/jats:bold> To evaluate the economic and clinical consequences of two different maintenance treatment modalities, administered to 6017 gastro\u2010oesophageal reflux disease patients at 451 gastroenterological centres in Italy.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Adult gastro\u2010oesophageal reflux disease patients received, at enrolment, an acute treatment of esomeprazole 40\u2003mg\/day for 4\u2003weeks and, if successfully treated, were randomized into two maintenance treatment strategies: esomeprazole 20\u2003mg\/day or esomeprazole on demand for 6\u2003months. A baseline endoscopy allowed the exclusion of grade II\u2013IV oesophagitis according to Savary\u2013Miller's classification. Burden of gastro\u2010oesophageal reflux disease was measured at baseline by the generic questionnaire Short\u2010Form 36 and by a disease specific instrument, quality of life in reflux and dyspepsia (QOLRAD), also administered at start and conclusion of maintenance period. Investigators were required to collect patient judgement about the degree of satisfaction with treatment effect on heartburn, with a 7\u2010point scale.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> A comparison between Short\u2010Form 36 scores and the normative source of the Italian general population suggested that symptomatic gastro\u2010oesophageal reflux disease patients experience a worse quality of life than the general population. At the end of the 4\u2010week treatment with esomeprazole 40\u2003mg all (QOLRAD) dimensions showed a statistically significant (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001) and clinically meaningful improvement.<\/jats:p><jats:p>Satisfaction level towards treatment was reported high in the total enrolled population after acute treatment with esomeprazole 40\u2003mg\/day (96.2% satisfied and 64.4% very satisfied). A statistically significant difference in (QOLRAD) scores was registered at the end of maintenance phase in favour of the continuous regimen, nevertheless the size of this difference was very small in all dimensions; similarly, the proportion of patients very satisfied was slightly higher in the continuous treatment arm (64.5%) than in the on\u2010demand arm (59.7%).<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Gastro\u2010oesophageal reflux disease can significantly impair health\u2010related quality of life and esomeprazole therapy allows immediate relief in the acute phase of the disease. Quality of life improvement was maintained during the 6\u2010month follow\u2010up with a slight difference in term of quality of life in reflux and dyspepsia scores and patients\u2019 satisfaction in favour of the continuous treatment strategy.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02558.x","type":"journal-article","created":{"date-parts":[[2005,8,11]],"date-time":"2005-08-11T12:53:45Z","timestamp":1123764825000},"page":"349-356","source":"Crossref","is-referenced-by-count":39,"title":["Quality of life in acute and maintenance treatment of non\u2010erosive and mild erosive gastro\u2010oesophageal reflux disease"],"prefix":"10.1111","volume":"22","author":[{"given":"F.","family":"PACE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"NEGRINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"WIKLUND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"ROSSI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"SAVARINO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"THE ITALIAN ONE INVESTIGATORS STUDY GROUP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,7,27]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000200911"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70025-8"},{"issue":"4","key":"e_1_2_7_4_2","first-page":"30S","article-title":"Long\u2010term management of gastroesophageal reflux disease and its complications","volume":"92","author":"Richter JE","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.4065\/76.1.102"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(99)00656-5"},{"key":"e_1_2_7_7_2","first-page":"217","article-title":"Quality of life scale for gastroesophageal reflux disease","volume":"183","author":"Velanovich V","year":"1996","journal-title":"J Am Coll Surg"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2004.01861.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(01)02591-6"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000016881"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03932.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000051885"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200321110-00002"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00354-9"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(03)00012-1"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.16.s4.11.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-001-9223-2"},{"key":"e_1_2_7_18_2","volume-title":"L'oesophage \u2010 Manuel et Atlas d'endoscopie","author":"Savary M","year":"1997"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03320536"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00107-3"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00108-5"},{"key":"e_1_2_7_22_2","volume-title":"Questionario sullo stato di salute SF\u201036. Manuale d'uso e guida all'interpretazione dei risultati","author":"Apolone G","year":"1997"},{"key":"e_1_2_7_23_2","first-page":"41","article-title":"Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease\u2010specific questionnaire (QOLRAD)","volume":"583","author":"Wiklund IK","year":"1998","journal-title":"Eur J Surg Suppl"},{"issue":"4","key":"e_1_2_7_24_2","first-page":"A\u2010601","article-title":"The impact of baseline scores on a relevant change and a minimal important difference (MID) in patient\u2010reported outcomes (PROS) in reflux disease","volume":"126","author":"Wiklund I","year":"2004","journal-title":"Gastroenterology"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025192100450"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200424040-00002"},{"key":"e_1_2_7_27_2","volume-title":"by SAS Institute Inc","author":"SAS release 8.02","year":"1999"},{"key":"e_1_2_7_28_2","volume-title":"Handling Missing Data in Quality of Life Questionnaires: Experience from Clinical Trials","author":"Halling K","year":"1999"},{"key":"e_1_2_7_29_2","first-page":"A102","article-title":"A quality of life (QOL) comparison of 2 strategies for long\u2010term treatment with esomeprazole in mild\u2010moderate erosive oesophagitis (EE)","volume":"53","author":"Delchier J","year":"2004","journal-title":"Gut"},{"key":"e_1_2_7_30_2","article-title":"Impact of moderate to severe GERD on health\u2010related quality of life and improvement with esomeprazole","author":"El\u2010Dika S","year":"2004","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_7_31_2","first-page":"A50","article-title":"Esomeprazole continuous versus on\u2010demand maintenance therapy in 1052 gastro\u2010oesophageal reflux disease patients: similar satisfaction but superior quality of life for once daily treatment","volume":"15","author":"Engels LGJB","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.3.3.341"},{"key":"e_1_2_7_33_2","first-page":"271","article-title":"Symptoms of gastro\u2010oesophageal reflux disease have a negative impact on health\u2010related quality of life","volume":"10","author":"Talley NJ","year":"2001","journal-title":"Qual Life Res"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01770.x"},{"key":"e_1_2_7_35_2","first-page":"A211","article-title":"Impact of H. pylori infection on quality of life during treatment with esomeprazole in patients with gastroesophageal reflux disease","volume":"51","author":"Knippig C","year":"2002","journal-title":"Gut"},{"issue":"238","key":"e_1_2_7_36_2","first-page":"22","article-title":"Esomeprazole is superior to ranitidine 150\u2003mg bid in maintaining quality of life (QoL) in patients with symptomatic GERD","volume":"38","author":"Wiklund I","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03932.x"},{"issue":"4","key":"e_1_2_7_38_2","first-page":"A200","article-title":"The effect of esomeprazole 40\u2003mg on healing, reflux symptoms and quality of life in patients with reflux oesophagitis","volume":"122","author":"Lauritsen K","year":"2002","journal-title":"Gastroenterology"},{"key":"e_1_2_7_39_2","article-title":"Cast Study Advisory Board. Quality of life (qol) in uninvestigated dyspepsia (ud) patients following treatment with esomeprazole (e) for 4 and 8\u2003weeks: the confirmatory acid suppression test (cast) study","author":"Armstrong D","year":"2004","journal-title":"Can J Gastroenterol"},{"issue":"4","key":"e_1_2_7_40_2","first-page":"A\u2010603","article-title":"Maintenance of improvement in quality of life dimensions and symptom control following initial treatment of upper GI symptoms with esomeprazole versus placebo in patients on long\u2010term NSAID therapy","volume":"126","author":"Talley NJ","year":"2004","journal-title":"Gastroenterology"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)80526-7"},{"issue":"1","key":"e_1_2_7_42_2","first-page":"148","article-title":"Esomeprazole improves quality of life in patients with upper GI symptoms associated with long\u2010term NSAID therapy","volume":"62","author":"Hawkey C","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"e_1_2_7_43_2","first-page":"150","article-title":"Upper GI symptoms reduce the quality of life for patients on long\u2010term NSAID therapy","volume":"62","author":"Wiklund I","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_44_2","first-page":"A68","article-title":"On demand versus continuous treatment with esomeprazolo 20\u2003mg once daily in subjects with healed erosive esofhagitis after initial healing with eso 40\u2003mg once daily. An open, randomized, Swedish multicenter study","volume":"53","author":"Sjostedt S","year":"2004","journal-title":"Gut"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02558.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02558.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:14:48Z","timestamp":1697231688000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02558.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,27]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02558.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02558.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,27]]}}}